Caerus Investment Advisors LLC Takes Position in Regeneron Pharmaceuticals, Inc. $REGN

Caerus Investment Advisors LLC acquired a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 1,329 shares of the biopharmaceutical company’s stock, valued at approximately $747,000.

Several other large investors have also made changes to their positions in REGN. Brighton Jones LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 261.8% during the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after buying an additional 686 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Regeneron Pharmaceuticals in the first quarter worth $226,000. Citizens Financial Group Inc. RI increased its position in Regeneron Pharmaceuticals by 237.4% during the second quarter. Citizens Financial Group Inc. RI now owns 2,659 shares of the biopharmaceutical company’s stock worth $1,396,000 after acquiring an additional 1,871 shares during the period. Dorsey & Whitney Trust CO LLC raised its stake in Regeneron Pharmaceuticals by 40.2% during the 2nd quarter. Dorsey & Whitney Trust CO LLC now owns 506 shares of the biopharmaceutical company’s stock valued at $266,000 after purchasing an additional 145 shares during the last quarter. Finally, Frank Rimerman Advisors LLC raised its stake in Regeneron Pharmaceuticals by 7.3% during the 2nd quarter. Frank Rimerman Advisors LLC now owns 981 shares of the biopharmaceutical company’s stock valued at $515,000 after purchasing an additional 67 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 0.3%

Shares of REGN opened at $759.05 on Wednesday. The company has a market capitalization of $80.25 billion, a P/E ratio of 18.26, a PEG ratio of 2.03 and a beta of 0.41. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $821.11. The business’s 50 day simple moving average is $769.26 and its 200-day simple moving average is $698.18. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.13 and a quick ratio of 3.39.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.74 by $0.70. The firm had revenue of $3.88 billion during the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The business’s revenue for the quarter was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $12.07 EPS. As a group, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 5th. Investors of record on Friday, February 20th were issued a $0.94 dividend. This is a positive change from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend was Friday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 9.05%.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $778.53, for a total value of $77,853.00. Following the completion of the sale, the director owned 17,803 shares in the company, valued at approximately $13,860,169.59. This trade represents a 0.56% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Bonnie L. Bassler sold 1,500 shares of the business’s stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the completion of the transaction, the director directly owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. This represents a 46.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 5,274 shares of company stock worth $4,142,738 in the last 90 days. Corporate insiders own 7.02% of the company’s stock.

Analyst Ratings Changes

REGN has been the topic of several research analyst reports. Evercore raised their price target on shares of Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an “outperform” rating in a research report on Thursday, January 22nd. Wall Street Zen lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. Canaccord Genuity Group increased their target price on shares of Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the company a “buy” rating in a research note on Thursday, December 4th. Guggenheim boosted their price target on Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the company a “buy” rating in a research note on Monday, February 9th. Finally, HSBC began coverage on Regeneron Pharmaceuticals in a report on Monday, November 24th. They issued a “buy” rating and a $255.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $802.27.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.